Dare Bioscience, Inc. · NASDAQ:DARE
Dare Bioscience — Investor Presentation (January 2018)
20 slides from Dare Bioscience's investor presentation, Jan 8, 2018
Slide 1: Delivering innovation by daring to be different
NASDAQ:DARE January 2018 Delivering innovation by daring to be different biotechnology for women, by women Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of DARÉ BIOSCIENCE, INC. (“dARE” OR THE “COMPANY”). THIS PRESENTATION INCLUDES CERTAIN INFORMATION OBTAINED FROM TRADE AND STATISTICAL SERVI
Slide 3: Delivering Innovation in Women's Health
Delivering Innovation in Women’s Health Mission: Identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. Deliver innovation by filling the development gap Fragmented market segment between earl
Slide 4: Corporate Summary
Corporate Summary Ovaprene™: convenient non-hormonal contraceptive method Unique combination approach seeks to generate effectiveness in the range of the birth control pill Enrollment to begin in early 2018 for Postcoital Test (PCT) Clinical Trial; trial completion expected in 2nd half 2019. 12 issu
Slide 5: Innovation in Contraception
Innovation in Contraception All about hormones Advances beyond “the pill” have largely focused on new combinations, doses, durations and modes of administration Successful hormonal commercial brands, easy to use NuvaRing® Merck’s hormonal monthly vaginal ring (2016 revenue: $777 million) Mirena® Bay
Slide 6: Contraception: Large Market with Compelling Needs
Contraception: Large Market with Compelling Needs The global market for contraception was $19 billion in 2015 and is estimated to grow over 6% to $33 billion in 2023. (1) 40 million women of reproductive age in the U.S. are currently using a contraceptive method, about 62% of the population. Fifty p
Slide 7: Ovaprene: New Contraceptive Category
Ovaprene™: New Contraceptive Category Provides monthly contraceptive protection without hormones Silicone reinforced ring with a soft, absorbable scaffolding that encircles a fluid-permeable barrier Non-braided, multi-filament mesh functions as a physical barrier to sperm Contraceptive-loaded silico
Slide 8: Need for Better "Typical Use" Non-Hormonal Efficacy
Need for Better “Typical Use” Non-Hormonal Efficacy A non-hormonal monthly option that is safe and effective, and provides protection over multiple weeks, could fill a current gap. Source: Guttmacher (www.guttmacher.org), FDA.gov
Slide 9: What do Contracepting Women Want?
What do Contracepting Women Want? Features desired most in birth control: Efficacy Ease of Use Ease of Adherence No or Low Side Effects Easy Reversal 67 percent of women report that the vaginal ring has most of the features deemed extremely important(1) 85 percent of women would prefer a monthly opt
Slide 10: What do Millennials Want?
What do Millennials Want? A survey of 1,000+ sexually active women aged 18-29 trying to avoid pregnancy revealed(1): 33% are uneasy about what taking the pill might mean for their fertility in the future 26% are scared by the medical warnings they see in the TV commercials 25% say taking something e
Slide 11: Why is Non-Hormonal Important?
Why is Non-Hormonal Important? Many women cannot tolerate hormones – breast tenderness, weight gain, mood swings, decreased sex drive and general discomfort Other women are contraindicated for long-term hormone use(1): Over 35 years old and smoke or have certain kinds of severe migraine headaches Ha
Slide 12: Ovaprene: Human Proof of Concept Study
Ovaprene™: Human Proof of Concept Study(1) Postcoital Test (PCT) Clinical Trial Study Design: Open-label, single-arm, pilot safety and tolerability study as a barrier contraceptive Patients: 21 women enrolled; all women completed one cycle of use Results: Postcoital testing revealed no viable sperm
Slide 13: Ovaprene: Strategy Forward
Ovaprene™: Strategy Forward U.S. Regulatory Strategy Previous FDA Request for Designation (RFD) determination Ovaprene™ will require a PMA with CDRH as lead review division Clinical path forward expected to be based on prior CDRH approvals (Example: Caya® diaphragm) Predictive efficacy postcoital te
Slide 14: Ovaprene: Valuation Drivers
Ovaprene™: Valuation Drivers J.L. Schwartz et al. / Contraception 78 (2008) 237–244. Schwartz JL, Weiner DH, Lai JJ, et al. Contraceptive efficacy, safety, fit, and acceptability of SILCS, a novel single-size diaphragm. 2014. 3 4 1 YEAR: 2 PCT Clinical Trial Caya® experience(1) - 14 months start to
Slide 15: Pricing Trends for Branded Contraceptive Products that Fill Gaps
Pricing Trends for Branded Contraceptive Products that Fill Gaps $41.27 $120.92* Average annual price increase: 12.4% *13 cycles equate to $1,571 per year (1) MediSpan Price Rx Select, January 2016. Average prices of 13 branded contraceptive products.
Slide 16: Financial Profile
Financial Profile Background : NASDAQ:DARE Publicly traded via stock purchase agreement (reverse merger), closed July 19, 2017 Cash at closing sufficient through 2 years, to value inflection point of lead candidate Ovaprene™ Balance Sheet Data: Cash $8.5 million at 9/30/17 6 million shares outstandi
Slide 17: Experienced Team to Move the Field Forward
Sabrina Martucci Johnson President and CEO WCG, Cypress Bioscience, Advanced Tissue Sciences, Baxter Healthcare Lisa Walters-Hoffert Chief Financial Officer ROTH Capital Partners, Citicorp Securities, Bank of America, Oppenheimer & Co. Mark Walters VP, Operations Pacira, SkyePharma, Alliance, Americ
Slide 18: Experienced Board of Directors
Experienced Board of Directors Roger Hawley (Chairman) Zogenix, Alios Biopharma, InterMune, Elan Susan Kelley, MD Cerulean, Bayer, BMS, ArQule William Rastetter, PhD Cerulean, GRAIL, Receptos, Illumina, IDEC Robin Steele, JD, LLM InterMune, Elan, Alvea, Alios Biopharma, Sabrina Martucci Johnson WCG,
Slide 19: Investment Highlights
Investment Highlights Ovaprene™: convenient non-hormonal contraceptive method Intended to provide protection over multiple weeks of use, requiring no intervention at the time of intercourse Seeks to generate effectiveness in the range of the birth control pill Near term catalyst - enrollment to begi
Slide 20: For more information
858-926-7655 innovations@darebioscience.com www.darebioscience.com For more information:
Dare Bioscience — Investor Presentation (January 2018) on 6ix